Cardiovascular-kidney-metabolic syndrome — a new concept of the association of risk factors and metabolic disorders within the cardiovascular and renal continuum. View on the issue
https://doi.org/10.15829/1560-4071-2024-5772
EDN: YQSFCR
Abstract
In 2023, the American Heart Association for the first time formally defined cardiovascular-kidney-metabolic (CKM) syndrome as a systemic disease characterized by pathophysiological interactions between metabolic risk factors, chronic kidney disease (CKD), and cardiovascular system, leading to multiple organ dysfunction and a common adverse cardiovascular outcomes. Data are presented based on the pathophysiological mechanisms and clinical manifestations that made it possible to define this syndrome through the interaction between metabolic risk factors, CKD and the cardiovascular system, leading to multiple organ dysfunction and a high level of adverse cardiovascular outcomes. A classification of this syndrome into stages has been determined, for each of which approaches to the diagnosis and management of patients have been defined. CKM syndrome reflects the influence of multisystem pathophysiological relationships embedded in a multi-level socially and clinically determined community of manifestations, the fusion of which specifies clinical outcomes.
About the Authors
G. G. Arabidze
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Moscow
M. N. Mamedov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow
References
1. Wang HH, Lee DK, Liu M, et al. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3):189-230. doi:10.5223/pghn.2020.23.3.189.
2. Ndumele ChE, Neeland IJ, Tuttle KR, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. 9 Oct. 2023. Circulation. 2023;148:1636-64. doi:10.1161/CIR.0000000000001186.
3. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32. doi:10.1016/j.jacc.2010.05.034.
4. Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, et al.; for the RIVANA Study Investigators. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19(1):195. doi:10.1186/s12933-020-01166-6.
5. Powell-Wiley TM, Poirier P, Burke LE, et al.; on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143:e984-e1010. doi:10.1161/CIR.0000000000000973.
6. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-86. doi:10.1097/HEP.0000000000000520.
7. Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022;102:248-60. doi:10.1016/j.kint.2022.05.012.
8. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:e840-e878. doi:10.1161/CIR.0000000000000664.
9. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics — 2017 update: a report from the American Heart Association [published corrections appear in Circulation. 2017;135:e646 and Circulation. 2017;136:e196. Circulation. 2017;135:e146-e603. doi:10.1161/CIR.0000000000000485.
10. Beckman JA, Schneider PA, Conte MS. Advances in revascularization for peripheral artery disease: revascularization in PAD. Circ Res. 2021;128:1885-912. doi:10.1161/CIRCRESAHA.121.318261.
11. Lloyd-Jones DM, Allen NB, Anderson CAM, et al.; on behalf of the American Heart Association. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146:e18-e43. doi:10.1161/CIR.000000000000107.
12. Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD Trial. Diabetes Care. 2007;30:1374-83. doi:10.2337/dc07-0048.
13. Wang K, Hu J, Luo T, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43:768-79. doi:10.1159/000489913.
14. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22. doi:10.1056/NEJMoa1812792.
15. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022;388:117-27. doi:10.1056/NEJMoa2204233.
16. Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:S1-S87. doi:10.1016/j.kint.2020.11.003.
17. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study: SAVE investigators. J Am Coll Cardiol. 1997;29:229-36. doi:10.1016/s0735-1097(96)00489-5.
18. Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45:909-18. doi:10.2337/dc21-1113.
19. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published corrections appear in Circulation. 2022;145:e1033, Circulation. 2022;146:e185, and Circulation. 2023;147:e674]. Circulation. 2022;145:e895-e1032. doi:10.1161/CIR.0000000000001063.
20. Beldhuis IE, Lam CSP, Testani JM, et al. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022;145:693-712. doi:10.1161/circulationaha.121.052792.
21. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460-70.doi:10.1161/circulationaha.121.057736.
22. Donato AA. Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk. Ann Intern Med. 2017;17;166(2):JC8. doi:10.7326/ACPJC-2017-166-2-008.
Supplementary files
- The combination of metabolic risk factors and chronic kidney disease within the cardiovascular-kidney-metabolic syndrome has been shown to be closely associated with the risk of adverse cardiovascular and renal outcomes.
- The pathogenesis of this syndrome is presented and its clinical and laboratory classification is proposed, highlighting the development stages and an effective approach to therapy.
- Risk algorithms that reflect the multiple adverse cardiovascular and renal outcomes that are common in patients with cardiovascular-kidney-metabolic syndrome can help better target therapy to proper subpopulations.
Review
For citations:
Arabidze G.G., Mamedov M.N. Cardiovascular-kidney-metabolic syndrome — a new concept of the association of risk factors and metabolic disorders within the cardiovascular and renal continuum. View on the issue. Russian Journal of Cardiology. 2024;29(5):5772. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5772. EDN: YQSFCR
Views:
1509
Email this article 